[ad_1]

Abstract

Cannabis sativa L. is a plant extended utilised for its textile fibers, seed oil, and oleoresin with medicinal and psychoactive properties. It is the principal supply of phytocannabinoids, with more than 100 compounds detected so far. In current years, a lot of consideration has been provided to the principal phytochemicals present in Cannabis sativa L., namely, cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC). Compared to THC, CBD has non-psychoactive effects, an benefit for clinical applications of anti-tumor positive aspects. The critique is created to supply an update relating to the multi-target effects of CBD in distinct sorts of cancer. The principal concentrate is on the most up-to-date in vitro and in vivo research that present information relating to the anti-proliferative, pro-apoptotic, cytotoxic, anti-invasive, anti-antiangiogenic, anti-inflammatory, and immunomodulatory properties of CBD collectively with their mechanisms of action. The most up-to-date clinical proof of the anticancer effects of CBD is also outlined. Furthermore, the principal elements of the pharmacological and toxicological profiles are provided.

Copyright © 2018 Elsevier B.V. All rights reserved.

Supply:Pubmed

 

 

PMID: 31775230 DOI: 10.3390/ijms20235905

 

 

Kis B1,two, Ifrim FCthree, Buda Vfour, Avram S1, Pavel IZ1, Antal Dfive, Paunescu Vtwo,six, Dehelean CA7, Ardelean Ffive, Diaconeasa Zeight, Soica C9, Danciu C1.

[ad_2]